Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecologic malignancies

R J Schilder1, R M Scher, R C Young

  • 1Fox Chase Cancer Center, Philadelphia, PA.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The sounds of silence.

Nature·2000
Same author

Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy.

Journal of the National Medical Association·2000
Same author

Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Fox Chase Network: Fox Chase Cancer Center's community hospital affiliation program.

The oncologist·2000
Same author

Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

Seminars in oncology·2000
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

New research is evaluating intraperitoneal P32 versus chemotherapy for early-stage ovarian cancer. Platinum-based chemotherapy remains a standard for advanced and recurrent disease, with Taxol emerging as a key salvage and potential front-line treatment.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Radiation Oncology

Background:

  • Limited new publications on early-stage ovarian cancer in the past year.
  • Established treatments like cisplatin and cyclophosphamide remain first-line for advanced disease (Stages III-IV).
  • Carboplatin is now a standard component of first-line treatment for advanced ovarian cancer.

Purpose of the Study:

  • To assess the benefits and toxicities of intraperitoneal P32 compared to cyclophosphamide and cisplatin for early-stage ovarian cancer.
  • To review current treatment strategies for advanced, recurrent, and non-epithelial ovarian cancers.
  • To evaluate emerging therapies like Taxol and high-dose chemotherapy.

Main Methods:

  • Review of recent studies and clinical trials in ovarian cancer treatment.

Related Experiment Videos

  • Comparison of intraperitoneal P32 with standard chemotherapy regimens.
  • Analysis of platinum-based chemotherapy, Taxol, altretamine, and ifosfamide in various ovarian cancer settings.

    • Main Results:

    • Cisplatin-based chemotherapy (BEP) shows activity in advanced dysgerminoma, offering fertility-sparing alternatives.
    • Cisplatin-based chemotherapy is active in mixed mullerian tumors, though prognosis is poorer than epithelial ovarian cancer.
    • High-dose chemotherapy with stem cell support is a promising approach for poor-prognosis disease.

    Conclusions:

    • Platinum-based chemotherapy is the cornerstone for recurrent ovarian cancer.
    • Taxol is a significant new option for salvage therapy and is being investigated for front-line use.
    • Intraperitoneal chemotherapy and biologic agents require further research for broader clinical application. Radiation therapy plays a limited role, except for P32 in early-stage disease.